吉非替尼治疗非小细胞肺癌优势人群的临床观察

Therapeutic Effect of Gefinitib in the Treatment of Dorminant Crowd of Non-small Cell Lung Cancer Patients

目的观察吉非替尼(ZD1839,IRESSA)治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)优势人群的疗效。方法对2008年1月至2009年6月间接受了吉非替尼(250 mg/d,口服)治疗的48例晚期NSCLC患者的客观疗效及不良反应进行观察,分析疾病缓解率及疾病控制率的相关因素。结果 48例患者中CR 1例,PR 16例,SD 22例,PD9例,疾病缓解率为35.4%,疾病控制率为81.3%,中位生存期(median survival time,MST)为8个月(95%CI,6～9个月)。结论选择优势人群针对性地使用吉非替尼,可获得较高疗效,并有助于指导吉非替尼的个体化治疗。

Objective To evaluate the efficacy of gefitinib（ZD1839,IRESSA） in the treatment of the dorminant patients with advanced non-small cell lung cancer（NSCLC）.Methods 48 patients received gefitinib treatment（250 mg/ d,po） in the department of medical oncology in Wuxi No.4 People＇s Hospital from 2008 Jan to 2009 Jun.The therapy efficancy and the adverse reaction were analyzed.The influence of different factors on complete remission rate and disease controlling rate was analyzed.Results There was 1 patient with CR,16 patients with PR,22 patients with SD and 9 with PD,the overall response rate was 35.4% and the disease control rate was 81.3%.The median survival time（MST） of 48 patient s with advanced NSCLC was 8 months（95%CI：6～9）.Conclusion Gefitinib therapy based on the selection in dorminant crowd would be helpful in the treatment of advanced NSCLC patients.